Mesenchymal stem cells (MSCs) have been found to aid in the treatment of autoimmune-related lung fibrosis. Interstitial pneumonia is the inflammation of alveoli, and affects patients with pulmonary fibrosis and other connective tissue diseases. Increased fibrosis is due to an overactive immune response--mainly cytotoxic T cells. Past therapies have tried to suppress all immune cells to lower pro-fibrotic molecules. Mesenchymal stem cells are able to selectively change the composition of T cells from cytotoxic to regulatory. Bone marrow derived stem cells interfered with overactive autoimmune processes, and promoted the repair of alveoli tissue.
Introduction of stem cells to fibrotic lungs decreased cytotoxic T cells--which release pro-inflammatory cytokines. The researchers noted that MSCs secreting high levels of the molecule TGF-β1 had the most potent antifibrotic effects. The specific immunomodulatory capabilities of MSCs have been vital in treating hyperactive immune responses.
Advances in stem cell based regenerative treatments are creating more effective treatment options for patients suffering from a wide variety of disease, trauma and injury. To learn more about stem cells, and how families can bank their own valuable stem cells by recovering the very powerful dental pulp stem cells during routine dental procedures; such as wisdom teeth extractions or the during the loss of baby teeth, visit StemSave or call 877-783-6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here.